Aan dit artikel is enkele uren gewerkt. Opzoeken, vertalen, plaatsen enz. Als u ons wilt ondersteunen dan kan dat via een al of niet anonieme donatie. Elk bedrag is welkom hoe klein ook. Klik hier als u ons wilt helpen kanker-actueel online te houden Wij zijn een ANBI organisatie en dus is uw donatie aftrekbaar voor de belasting.

20 november 2012:

Een nieuwe studie bevestigt dat Enterale voeding - sonde voeding effectiever is dan parenterale voeding - voeding via infuus of katheter bij chemo bij slokdarmkanker. Enterale voeding vermindert de bijwerkingen van chemo en verhgroot de effectiviteit. Onderaan hebben we het abstract van deze studie waarvan het volledige studierapport gratis is in te zien: Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer toegevoegd aan onderstaande informatie uit maart 2012.

31 maart 2012: Bron: Eur Surg Res. 2012 Mar 1;48(2):79-84. [Epub ahead of print]

Enterale voeding (via sonde voeding) starten voordat operatie plaatsvindt van slokdarmkanker vermindert significant de kansen op levensbedreigende complicaties tijdens de operatie en versnelt het herstel na de operatie significant in vergelijking met parenterale voeding (via infuus) na de operatie. Dit blijkt uit een gerandomiseerde studie met totaal 154 patiënten met slokdarmkanker die daarvoor werden geopereerd.

Hier het abstract van de studie. Als u hier klikt kunt u het volledige studiie rapport tegen betaling inzien.

Early Enteral Nutrition Reduces the Rate of Life-Threatening Complications after Thoracic Esophagectomy in Patients with Esophageal Cancer

Eur Surg Res. 2012 Mar 1;48(2):79-84. [Epub ahead of print]

Early Enteral Nutrition Reduces the Rate of Life-Threatening Complications after Thoracic Esophagectomy in Patients with Esophageal Cancer.

Fujita T, Daiko H, Nishimura M.

Source

Division of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.

Abstract

Background: Early postoperative enteral nutrition has been suggested to improve the nutritional status of patients after esophageal surgery. However, whether enteral nutrition decreases rates of surgical complications and increases the completion rate of the clinical management pathway is unclear.

Methods: We analyzed 154 patients who were randomly assigned to either an enteral or parenteral nutrition group after undergoing esophagectomy, compared the incidence of surgical complications, and evaluated the completion rate of the clinical pathway. In these 2 patient groups, perioperative management was performed through identical clinical pathways, except for nutrition.

Results: The overall rate of surgical complications of any type did not differ between patients who received early enteral nutrition and those who did not (p = 0.50); however, the rate of life-threatening surgical complications was significantly lower in patients who received early enteral nutrition (p = 0.02). The rate of non-life-threatening surgical complications did not differ between the groups (p = 0.98). In patients who received enteral nutrition, the completion rate of the clinical pathway was higher (p = 0.03), and the postoperative hospital stay was shorter (p = 0.04).

Conclusions: Early enteral nutrition reduces the incidence of life-threatening surgical complications and improves the completion rate of the clinical pathway for thoracic esophagectomy.

PMID:: 22377820; [PubMed - as supplied by publisher]

Compared with parenteral support, enteral nutrition support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers

Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.

Miyata H, Yano M, Yasuda T, Hamano R, Yamasaki M, Hou E, Motoori M, Shiraishi O, Tanaka K, Mori M, Doki Y.

Source

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. hmiyata@gesrug.med.osaka-u.ac.jp

Abstract

BACKGROUND & AIMS:

Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer.

METHODS:

Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n = 47) or PN (n = 44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy.

RESULTS:

Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p = 0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17% vs 41%, p = 0.011, neutropenia: 36% vs 66%, p = 0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly.

CONCLUSIONS:

Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers.